NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial.
In this trial, patients are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests.
-- The prosecution on Monday rested its case against Pedro Abad, the former Linden, N. police officer accused of driving drunk the wrong direction on the West Shore Expressway and slamming into a tractor trailer, killing two of his passengers.
The trial seeks to determine whether treating cancer based on these specific genetic changes is effective.
There are 19 treatment arms that are currently open to patients, each enrolling patients whose tumors have a specific genetic change. However, a few treatment arms address more common genetic changes, and for those up to 70 patients per arm will be enrolled.
Patients with advanced solid tumors, lymphomas, or myeloma may be eligible for MATCH, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment.
A goal for the study is for about 25% of patients to have rare or uncommon cancers.